

REMARKS

The specification is amended and a substitute Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825.

Hereto is an attached substitute Sequence Listing in paper and computer readable format. The paper copy and computer readable copy of the substitute Sequence Listing are the same. The Sequence Listing does not include new matter.

CONCLUSION

Entry of the substitute Sequence Listing and favorable consideration are respectfully requested.

To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.

Respectfully submitted,
McDERMOTT, WILL & EMERY

Date: Apr. 14, 2004

By: Kelli N. Watson
Kelli N. Watson
Registration No. 47,170

600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
(202) 756-8351 (Direct)
(202) 756-8087 (Facsimile)